12-week Study of NFX-179 Gel in Subjects With Epidermal Nevi

12-Week Clinical Study to Determine the Safety, Tolerability, and Clinical Effect of NFX-179 Gel in Subjects With Epidermal Nevi

NCT05195762•Albert Chiou

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Epidermal NeviNevus Sebaceus

Interventions

NFX-179 Gel 1.50%

Locations

United States

Locations (1)

Stanford University

Redwood City, California, United States

Key Dates

Start Date

June 1, 2023

Primary Completion Date

June 1, 2024

Completion Date

December 1, 2024

Last Updated

May 28, 2024

Sponsors

Lead Sponsor

Albert Chiou

Collaborators

NFlection Therapeutics, Inc.

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 28, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions